Drug
Kfa115
Kfa115: highest development phase Phase 1, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| KFA115 NCT05544929 | Phase 1 | Carcinoma, Non-Small-Cell Lung |
Latest
No recent events.
Follow Kfa115 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.